Get the Stockscreener App
15.24
2.70%
0.40
Immunovant Inc stock is traded at $15.24, with a volume of 1.40M.
It is up +2.70% in the last 24 hours and down -15.05% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.
See More
Previous Close:
$14.84
Open:
$14.96
24h Volume:
1.40M
Relative Volume:
1.12
Market Cap:
$2.66B
Revenue:
-
Net Income/Loss:
$-382.71M
P/E Ratio:
-5.8168
EPS:
-2.62
Net Cash Flow:
$-325.64M
1W Performance:
+0.13%
1M Performance:
-15.05%
6M Performance:
-28.35%
1Y Performance:
-51.46%
1-Day Range:
$14.79
$15.38
1-Week Range:
$14.50
$15.52
52-Week Range:
$12.72
$34.47
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-580-3099
Address
320 WEST 37TH STREET, NEW YORK, NY
Compare IMVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
15.24 | 2.66B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Detecting support and resistance levels for Immunovant Inc.July 2025 Spike Watch & Weekly Top Performers Watchlists - Newser
How to recover losses in Immunovant Inc. stock2025 Stock Rankings & AI Forecasted Stock Moves - Newser
Key metrics from Immunovant Inc.’s quarterly dataMarket Movers & AI Based Trade Execution Alerts - Newser
Pattern recognition hints at Immunovant Inc. upsideJuly 2025 Spike Watch & Community Consensus Trade Signals - Newser
How to forecast Immunovant Inc. trends using time seriesPortfolio Update Summary & Low Risk High Reward Trade Ideas - Newser
Immunovant Inc. stock volume spike explainedJuly 2025 Market Mood & Precise Swing Trade Entry Alerts - Newser
Using R and stats models for Immunovant Inc. forecastingJuly 2025 Action & Verified Entry Point Detection - Newser
Immunovant Inc. stock trendline breakdownQuarterly Growth Report & Real-Time Market Sentiment Reports - Newser
Full technical analysis of Immunovant Inc. stockEarnings Overview Report & Growth Focused Entry Point Reports - Newser
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus - MSN
Technical Bounce Expected in Immunovant Inc. Next WeekDividend Hike & Weekly Setup with High ROI Potential - thegnnews.com
Immunovant, Inc. shares fall 3.83% intraday after law firm investigation announcement. - AInvest
Immunovant shares fall 5.54% premarket after law firm investigation announcement. - AInvest
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc.IMVT - Business Wire
Immunovant Reports Progress and Financial Results - TipRanks
Immunovant price target lowered to $57 from $58 at Citi - MSN
Chart based exit strategy for Immunovant Inc.Trade Analysis Report & Verified Swing Trading Watchlist - Newser
Immunovant (NASDAQ:IMVT) Price Target Cut to $30.00 by Analysts at Bank of America - Defense World
Immunovant (NASDAQ:IMVT) Given New $37.00 Price Target at JPMorgan Chase & Co. - Defense World
Immunovant Receives Buy Rating from Guggenheim with $44 Price Target - AInvest
IMVT: Analyst Jason Gerberry Lowers Price Target to $30, Maintains 'Buy' Rating - AInvest
Immunovant's Q1 Loss Narrower Than Expected, Pipeline In Focus - Barchart.com
Chart Patterns Forming a Bullish Setup in Immunovant Inc.Reliable Investment Entry Signals Confirmed by Charts - 선데이타임즈
What makes Immunovant Inc. stock price move sharplyWealth Tripler Trade List - newsyoung.net
Why Immunovant Inc. stock attracts strong analyst attentionSmart Money Strategy for Growth Stocks - Newser
Immunovant Spends More To Move Key Drug Trials Forward - Finimize
Immunovant Pours More Into Trials And Investors Aren’t Flinching - Finimize
Immunovant Posts 34% R&D Jump in Q1 - AOL.com
Stifel lowers Immunovant stock price target to $50 from $61, maintains Buy - Investing.com Canada
Assessing Immunovant's Strategic Expansion and Financial Viability Amid Widening Losses - AInvest
Immunovant's Fiscal Q1 Net Loss Widens - MarketScreener
Immunovant Posts 34% R&D Jump in Q1 - The Motley Fool
Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Net Loss $0.71 a Share, vs. FactSet Est of $0.68 Loss - MarketScreener
Immunology company Immunovant's Q1 net loss widens to $120.6 mln - MarketScreener
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025 - The Manila Times
Immunovant Launches New Clinical Trials, Reports $599M Cash Position | IMVT Stock News - Stock Titan
Candlestick Reversal Detected on Immunovant Inc.’s ChartReal Time Alerts Based on AI Prediction Triggered - metal.it
Combining price and volume data for Immunovant Inc.Free Investment Strategy With Predictable Gains - Newser
Immunovant Inc. Company Revenue and Profit Trends: A Deep DiveTechnical Analysis of Growth Stock Opportunities - Newser
Is Immunovant Inc. a growth stock or a value stockStrong return on investment - Jammu Links News
How does Immunovant Inc. compare to its industry peersAchieve rapid portfolio appreciation today - Jammu Links News
What are the technical indicators suggesting about Immunovant Inc.Massive wealth growth - Jammu Links News
Is Immunovant Inc. a good long term investmentFastest-growing stock picks - Jammu Links News
Should I hold or sell Immunovant Inc. stock in 2025Sky-high return potential - Jammu Links News
When is Immunovant Inc. stock expected to show significant growthTriple-digit growth rates - Jammu Links News
How volatile is Immunovant Inc. stock compared to the marketUnmatched market gains - Jammu Links News
What drives Immunovant Inc. stock priceCapitalize on market opportunities with confidence - Jammu Links News
What institutional investors are buying Immunovant Inc. stockOutperformance with explosive growth - Jammu Links News
Is it the right time to buy Immunovant Inc. stockFree Stock Movement Tracking - Jammu Links News
What catalysts could drive Immunovant Inc. stock higher in 2025Breakthrough wealth creation - Jammu Links News
Immunovant (IMVT) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Geffner Michael | Chief Medical Officer |
Jul 23 '25 |
Sale |
18.15 |
2,385 |
43,288 |
221,825 |
| Geffner Michael | Chief Medical Officer |
Jul 09 '25 |
Sale |
17.24 |
1,160 |
19,998 |
224,210 |
| Stout Jay S | Chief Technology Officer |
Jul 09 '25 |
Sale |
17.24 |
1,519 |
26,188 |
207,724 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):